Connex 3: Evaluating the Efficacy and Safety of BI 425809 for Cognitive Impairment in Schizophrenia

Connex 3 is a phase 3, double-blind, placebo-controlled medication study. This trial aims to assess the efficacy of BI 425809 10mg, taken once daily for 26 weeks, in improving cognitive impairment and daily functioning, as well as its safety. Inclusion criteria: diagnosis of schizophrenia; male or female aged 18-50 years; stable medication for at least 3 months; no hospitalisation in the last 3 months.